El-Ghobarey A F, Mavrikakis M E, Macleod M, Reynolds P M, Capell H A, Spencer D G, Balint G, Mathieu J P, McAllister T, Cooney A, Dick W C
Q J Med. 1978 Jul;47(187):385-400.
Two studies with levamisole in rheumatoid arthritis are reported. In the first study of 30 patients levamisole was superior to placebo in terms of pain relief, reduction in articular tenderness, duration of morning stiffness, erythrocyte sedimentation rate (ESR), and radioisotope uptake in knee and wrist joints. There were no consistent differences in lymphocyte function, immunoglobin or complement concentration, or polymorphonuclear granulocytic function. In the second study forty patients were commenced on treatment with either gold or levamisole. At the end of one year there were significant improvements with both regimens in pain score, joint tenderness and ESR. The patients on levamisole showed significant improvement of duration of morning stiffness, while the patients on gold showed significant improvement of rheumatoid factor titre and left hand grip, but there were no significant differences between the two regimens.
报道了两项关于左旋咪唑治疗类风湿性关节炎的研究。在第一项针对30名患者的研究中,就疼痛缓解、关节压痛减轻、晨僵持续时间、红细胞沉降率(ESR)以及膝关节和腕关节的放射性同位素摄取而言,左旋咪唑优于安慰剂。淋巴细胞功能、免疫球蛋白或补体浓度以及多形核粒细胞功能方面没有一致的差异。在第二项研究中,40名患者开始接受金制剂或左旋咪唑治疗。一年结束时,两种治疗方案在疼痛评分、关节压痛和ESR方面均有显著改善。服用左旋咪唑的患者晨僵持续时间有显著改善,而服用金制剂的患者类风湿因子滴度和左手握力有显著改善,但两种治疗方案之间没有显著差异。